Human Cellular Models for Predicting Individual Responses to Cystic Fibrosis Transmembrane Conductance Regulator- Directed Therapeutics (R43/R44)

Funding Opportunity RFA-HL-15-027 from the NIH Guide for Grants and Contracts. This program will support the commercial development and validation of novel in vitro human cell-based tools for predicting the responses of individual patients to cystic fibrosis transmembrane conductance regulator (CFTR)-directed therapeutics for cystic fibrosis (CF) lung disease. NHLBI anticipates that outcomes of successful SBIR projects will help attract strategic partners or investors to support ultimate commercialization of a personalized medicine platform that could accelerate translation of CFTR-directed therapy in patients with CF lung disease.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding